NATUREWISE BIOTECH & MEDICALS CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.7 TWD | -1.59% |
|
-1.59% | -9.36% |
| Sales 2022 | 229M 7.08M 564M | Sales 2023 | 160M 4.96M 395M | Capitalization | 1.34B 41.61M 3.31B |
|---|---|---|---|---|---|
| Net income 2022 | 30M 929K 74.03M | Net income 2023 | 10M 310K 24.68M | EV / Sales 2022 | 5.45 x |
| Net cash position 2022 | 491M 15.22M 1.21B | Net cash position 2023 | 467M 14.48M 1.15B | EV / Sales 2023 | 5.47 x |
| P/E ratio 2022 |
57.9
x | P/E ratio 2023 |
136
x | Employees | 32 |
| Yield 2022 |
1.42% | Yield 2023 |
-
| Free-Float | 40.6% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.59% | ||
| 1 week | -1.59% | ||
| Current month | -1.59% | ||
| 1 month | -1.98% | ||
| 3 months | -1.20% | ||
| 6 months | +10.76% | ||
| Current year | -9.36% |
1 week
24.05
25.30
1 month
24.0025.65
Current year
23.5527.55
1 year
22.0536.75
3 years
19.5554.50
5 years
17.7554.50
10 years
9.9954.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chung Yang Huang
CEO | Chief Executive Officer | - | 07/10/07 |
Yue Ling Yang
DFI | Director of Finance/CFO | - | 28/02/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chung Yang Huang
CEO | Chief Executive Officer | - | 07/10/07 |
Ching Yang Su
BRD | Director/Board Member | - | 21/05/15 |
Bor Song Liang
BRD | Director/Board Member | - | 22/06/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 24.7 | -1.59% | 16,422 |
| 02/05/24 | 25.1 | 0.00% | 37,304 |
| 30/04/24 | 25.1 | +0.40% | 14,134 |
| 29/04/24 | 25 | -0.40% | 118,458 |
| 26/04/24 | 25.1 | 0.00% | 31,306 |
End-of-day quote Taipei Exchange, May 02, 2024
More quotes
NatureWise Biotech & Medicals Corporation is principally engaged in the wholesales and retailing of Chinese and Western medicine, medical equipment, agricultural and livestock products and cosmetics. The Company's products mainly include medicines and healthcare products. The Company's products are mainly applied to reduce hypercholesterolemia and regulate physiological function and physical fitness. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -9.36% | 37.71M | |
| +19.98% | 43.48B | |
| +20.67% | 22.65B | |
| +14.56% | 14.73B | |
| +14.32% | 13.79B | |
| +44.72% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B |
- Stock Market
- Equities
- 4732 Stock
